Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373092 | 1.00 | MAPT (0.67) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5373087 | 1.00 | MAPT (0.67) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5365163 | 0.87 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5365160 | 0.87 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5365166 | 0.87 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5367793 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5367797 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5367801 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5371066 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2KDREGFRKMT2A | |
| SCHEMBL5371078 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2KDREGFRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5789427-A | ANTITUMOR, ANTICANCER AGENTS | SUGEN, INC. (US) | 1998-08-04 | — | — | US | claimed |
| US-7217737-B2 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2004-12-02 | — | — | US | disclosed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | disclosed |
| US-20020068687-A1 | Methods and compositions for inhibiting cell proliferative disorders | CHEN HUI (US) | 2002-06-06 | — | — | US | disclosed |
| US-6225346-B1 | FOR THERAPY AND PROPHYLAXIS OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5935993-A | TYROSINE KINASE INHIBITORS; TREATMENT OF CELL GROWTH, CELL DIFFERENTIATION DISORDERS | SUGEN, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5891917-A | MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES | SUGEN, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5789427-A | ANTITUMOR, ANTICANCER AGENTS | SUGEN, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5773476-A | KINASE INHIBITORS | SUGEN, INC. (IL) | 1998-06-30 | — | — | US | disclosed |
| WO-1996040629-A1 | TYRPHOSTIN-LIKE COMPOUNDS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | ERBB2, EGFR, MKI67 | MAPT 2232/4885SMN1; SMN2 3362/4885KDR 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.